Literature DB >> 19945308

A gene signature of primary tumor identifies metastasized seminoma.

Matthias Port1, Yu Wang, Hans Ulrich Schmelz, Tobias Pottek, Viktor Meineke, Christian Ruf, Michael Abend.   

Abstract

BACKGROUND: The aim of this study was the prediction of metastatic status in seminoma based on examination of the primary tumor.
METHODS: Total RNA was isolated from metastasized seminoma (n = 10, T1N1-2M0), non-metastasized seminoma (n = 21, T1-3N0M0), and corresponding normal tissues. Pooled RNA from 10 biopsies of each tissue type was hybridized on whole genome microarrays for screening purposes. Ninety-two selected gene candidates were quantitatively examined using real-time quantitative polymerase chain reaction (RTQ-PCR).
RESULTS: Agreement in gene expression was 88% between the whole genome microarrays and RTQ-PCR. Metastasized seminoma showed 1,912 up-regulated and 2,179 down-regulated genes with ≥ 2-fold differences in gene expression compared non-metastasized seminoma. RTQ-PCR of selected genes showed that mean gene expression values were significantly reduced in metastasized compared with non-metastasized seminoma. The presence of metastases could be predicted based on an 85-gene expression signature by using logistic regression. Sensitivity and accuracy of the 10-fold cross-validation model were 77.8% and 84.2%, respectively.
CONCLUSION: A logistic regression model using an 85 gene expression signature allowed identification of metastasized seminoma from the primary tumor with a sensitivity of 77.8%.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19945308     DOI: 10.1016/j.urolonc.2009.08.008

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  5 in total

1.  Prediction of metastatic status in non-seminomatous testicular cancer.

Authors:  C G Ruf; S Sachs; N Khalili-Harbi; H Isbarn; W Wagner; C Matthies; V Meineke; M Fisch; F K Chun; M Abend
Journal:  World J Urol       Date:  2013-10-29       Impact factor: 4.226

2.  Discriminating metastasised from non-metastasised seminoma based on transcriptional changes in primary tumours using NGS.

Authors:  C G Ruf; H-U Schmelz; M Port; W Wagner; C Matthies; B Müller-Myhsok; V Meineke; M Abend
Journal:  Br J Cancer       Date:  2014-05-01       Impact factor: 7.640

3.  Clinically apparent and occult metastasized seminoma: almost indistinguishable on the transcriptional level.

Authors:  Christian G Ruf; Matthias Port; Hans-Ulrich Schmelz; Walter Wagner; Felix Müller; Sven Senf; Cord Matthies; Bertram Müller-Myhsok; Viktor Meineke; Michael Abend
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

4.  Small RNAs in the peripheral blood discriminate metastasized from non-metastasized seminoma.

Authors:  Christian G Ruf; Daniela Dinger; Matthias Port; Hans-Ulrich Schmelz; Walter Wagner; Cord Matthies; Bertram Müller-Myhsok; Viktor Meineke; Michael Abend
Journal:  Mol Cancer       Date:  2014-03-06       Impact factor: 27.401

5.  Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.

Authors:  Jan K Hennigs; Julia Müller; Matti Adam; Joshua M Spin; Emilia Riedel; Markus Graefen; Carsten Bokemeyer; Guido Sauter; Hartwig Huland; Thorsten Schlomm; Sarah Minner
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.